Senores Pharmaceuticals Ltd
Price Range
₹372 - ₹391
Min. Quantity
38
Closes on
24 December 2024
Min. investment
₹14,858/494 Shares
Senores Pharmaceuticals Ltd IPO Timeline
Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre. Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company.
| Event | Date |
|---|---|
| Senores Pharmaceuticals Ltd IPO Opening Date | 20 December 2024 |
| Senores Pharmaceuticals Ltd IPO Closing Date | 24 December 2024 |
| Basis of Allotment | 26 December 2024 |
| Initiation of Refunds | 26 December 2024 |
| Credit of Shares to Demat | 27 December 2024 |
| Senores Pharmaceuticals Ltd IPO Listing Date | 30 December 2024 |
Senores Pharmaceuticals Ltd IPO Details
| Senores Pharmaceuticals Ltd IPO Date | 20 December 2024 to 24 December 2024 |
| Senores Pharmaceuticals Ltd IPO Face Value | ₹10 per share |
| Senores Pharmaceuticals Ltd IPO Price | ₹372 to ₹391 per share |
| Senores Pharmaceuticals Ltd IPO Lot Size | 38 |
| Issue Size | Shares of ₹10 (aggregating up to ₹582.11 Cr) |
| Fresh Issue | Shares of ₹10 (aggregating up to ₹500 Cr) |
| Offer for Sale | Shares of ₹10 (aggregating up to ₹82.11 Cr) |
| Issue Type | (Book Built Portion) |
| Listing At | BSE, NSE |
| QIB Shares Offered | Not more than 45,93,216 of the Net Offer |
| Retail Shares Offered | Not less than 15,46,586 of the Net Offer |
| NII (HNI) Shares Offered | Not less than 23,19,879 of the Net Offer |
| Company Promoters | Swapnil Jatinbhai, Ashokkumar Vijaysingh Barot, Anar Swapnil Shah |
Senores Pharmaceuticals Ltd IPO Lot Size
The Senores Pharmaceuticals Ltd IPO lot size is 38 shares. A retail-individual investor can apply for up to 13 lots (494 shares or ₹1,93,154).
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Minimum | 1 | 38 | ₹14,858 |
| Maximum | 13 | 494 | ₹1,93,154 |
- Strengths
- Risks
- Opportunities
- Ability to cater to the Regulated Markets of US, Canada and the United Kingdom through our US FDA approved formulation manufacturing facility in the US.
- Distinct niche product portfolio built in a short span for Regulated Markets of US, Canada and the United Kingdom.
- Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets, US, Canada and the United Kingdom.
- Presence in the Emerging Markets with a product portfolio, including specialty or complex products.
- R&D capabilities driving our differentiated portfolio of products.
- Professional management teams for our diverse business verticals.
Company Financials
Senores Pharmaceuticals Ltd Financial Information (Restated)
| Period Ended | Total Assets | Total Revenue | Profit After Tax |
|---|---|---|---|
| 03-2024 | 285.86 | 40.85 | 0.81 |
| 03-2023 | 102.63 | 17.52 | 1.83 |
| 03-2022 | 55.17 | 14.48 | 0.68 |
| Amount in ₹ Crore | |||
Objects of the Issue
The company proposes to utilise the Net Proceeds from the Fresh Issue towards funding the following objects:
- Funding the capital expenditure requirements by investment in of one of your its subsidiary Havix,for setting up a mfg facility for the production of sterlie injection in its Atlanta Facility
- Re-payment/pre-payment in full or in part of certain borrowings availed by the company and its subsidiary namely Havix Ratnatris and PSI
- Funding the working capital requirements of the company and its subsidiary namely SPI ad Ratnatris
- Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes
- Investment in its subsidiary namely Havix for re-payment/pre-payment in full or in part of certain borrowings availd by the subsidiaries
- Investment in its subsidiary namely SPI and Ratnatri to fund their working capital requirements
Senores Pharmaceuticals Ltd IPO Promoter Holding
| Pre Issue Share Holding | 11.43% |
| Post Issue Share Holding | 7.71% |
Senores Pharmaceuticals Ltd IPO Subscription Status (Bidding Detail)
The Senores Pharmaceuticals Ltd IPO is subscribed 93.41 times on 24 December 2024 05:00:00 PM. The public issue subscribed 89.23 times in the retail category, 94.66 times in the QIB category, and 96.11 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | QIB | NII | Retail | Employee | Total |
| Subscription (times) | 94.66 | 96.11 | 89.23 | 19.92 | 93.41 |
Senores Pharmaceuticals Ltd IPO Prospectus
Senores Pharmaceuticals Ltd IPO Listing Date
| Listing Date | 30 December 2024 |
| BSE Script | 544319 |
| NSE Symbol | SENORES |
| Listing In | BSE, NSE |
| ISIN | INE0RB801010 |
| IPO Price | ₹391 |
| Face Value | ₹10 |
Company Contact Information
#.1101-1103 11th Flr South TwrAmbali Bopal Road,Ahmedabad-380054
Phone: +91-79-2999 9857
Email: cs@senorespharma.com
Website: www.senorespharma.com
Senores Pharmaceuticals Ltd IPO Registrar
Senores Pharmaceuticals Ltd IPO Lead Manager(s)
- Equirus Capital Pvt Ltd
- Ambit Pvt Ltd
- Nuvama Wealth Management Ltd
FAQ
What is the issue size of Senores Pharmaceuticals Ltd IPO?
I have pre-applied for Senores Pharmaceuticals Ltd IPO. When will my order get placed?
In case of pre-apply, your IPO order will be placed on the Exchange as soon as the official bidding for TBI Corn Ltd IPO begins. You will receive a UPI request within 24 hours after the bidding period opens.